Resistant hypertension has a high prevalence and is associated with high morbidity and mortality. The Rheos Baroreflex Hypertension Therapy System is an implantable device that offers a completely new approach to treating patients with resistant hypertension by electrically activating the carotid baroreflex. Preliminary results from current feasibility clinical trials have shown sustained decreases in blood pressure after 1 year. The pivotal trial for US FDA approval and market release is currently ongoing. This article profiles the Rheos System and evaluates the treatment of resistant hypertension in general.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1586/17434440.5.1.33 | DOI Listing |
J Phys Ther Sci
January 2025
Center for Frontier Medical Engineering, Chiba University, Japan.
[Purpose] The safety and physiological effects of combined training with breathing resistance and sustained physical exertion in middle-aged and older adults remain unclear. This pilot study investigated the safety and physiological benefits of this training method in older adults. [Participants and Methods] Participants aged 55-75 without respiratory, circulatory, or metabolic diseases were randomly divided into two groups: a combined breathing and physical training group and a control group.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Diabetic cardiomyopathy (DMCM), defined as left ventricular dysfunction in the setting of diabetes mellitus without hypertension, coronary artery disease or valvular heart disease, is a well-recognized entity whose prevalence is certainly predicted to increase alongside the rising incidence and prevalence of diabetes mellitus. The pathophysiology of DMCM stems from hyperglycemia and insulin resistance, resulting in oxidative stress, inflammation, cardiomyocyte death, and fibrosis. These perturbations lead to left ventricular hypertrophy with associated impaired relaxation early in the course of the disease, and eventually culminating in combined systolic and diastolic heart failure.
View Article and Find Full Text PDFAm J Physiol Endocrinol Metab
January 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Miami, Miller School of Medicine, Miami Florida.
Intermittent hypoxemia (IH), a pathophysiologic consequence of obstructive sleep apnea (OSA), adversely affects insulin sensitivity, insulin secretion, and glucose tolerance. Nifedipine, an L-type calcium channel blocker frequently used for treatment of hypertension, can also impair insulin sensitivity and secretion. However, the cumulative and interactive repercussions of IH and nifedipine on glucose homeostasis have not been previously investigated.
View Article and Find Full Text PDFJMIR Dermatol
January 2025
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
Background: Online digital materials are integral to patient education and health care outcomes in dermatology. Acanthosis nigricans (AN) is a common condition, often associated with underlying diseases such as insulin resistance. Patients frequently search the internet for information related to this cutaneous finding.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Department of Hypertension and Vascular Disease, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Aims: Previous studies have shown that eGDR and TyG, as indicators of insulin resistance (IR), were key risk factors for cardiovascular disease (CVD). Our study further explored the relationship between eGDR change and new-onset CVD, and compared the predictive value of eGDR change, eGDR and TyG.
Materials And Methods: A total of 2895 participants without CVD at baseline from the China Health and Retirement Longitudinal Study (CHARLS) were included, using K-means clustering and cumulative eGDR to measure eGDR change between 2012 and 2015.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!